EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated

Zana Karami, Keywan Mortezaee, Jamal Majidpoor

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110648 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Zana Karami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Hauptthemen laut MEDLINE: B7-H1 Antigen, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 75 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI) therapy suffers from tumor resistance and relapse in majority of patients due to the suppressive tumor immune microenvironment (TIME). Advances in the field have brought about development of fusion proteins able to target two signaling simultaneously and to exert maximal anti-cancer immunity. Bispecific inhibitors of transforming growth factor (TGF)-β signaling and programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) are developed to reduce the rate of relapse and to achieve durable anti-cancer therapy. TGF-β is well-known for its immunosuppressive activity, and it takes critical roles in promotion of all tumor hallmarks. Bispecific anti-PD-(L)1/TGF-β inhibitors reinvigorate effector activity of CD8+ T and natural killer (NK) cells, hamper regulatory T cell (Treg) expansion, and increase the density of anti-tumor type 1 macrophages (M1). Responses to the bispecific approach are higher compared with solo anti-PD-(L)1 or TGF-β targeted therapy, and are seemingly more pronounced in human papillomavirus (HPV)+ patients. High expression of PD-L1 or immune-excluded phenotype in a tumor can also be markers of better response to the bispecific strategy. Besides, anti-PD-(L)1/TGF-β inhibitor therapy can be used safely with other therapeutic modalities including vaccination, radiation and chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenNeoplasmsHumansTransforming Growth Factor betaSignal TransductionImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

Immune checkpoint inhibitor (ICI)Programmed death-1 (PD-1)Programmed death-ligand 1 (PD-L1)ResistanceTransforming growth factor (TGF)Tumor immune microenvironment (TIME)

Substanzen

B7-H1 AntigenTransforming Growth Factor beta

Autor:innen und Institutionen

  • Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
  • Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran. Electronic address: keywan987@yahoo.com.
  • Department of Anatomy, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, Iran.

Zitieren

APA

Karami, Z., Mortezaee, K., & Majidpoor, J. (2023). Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110648

Vancouver

Karami Z, Mortezaee K, Majidpoor J. Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110648

BibTeX
@article{Karami2023,
  author = {Karami, Zana and Mortezaee, Keywan and Majidpoor, Jamal},
  title = {Dual anti-PD-(L)1/TGF-β inhibitors in cancer immunotherapy – Updated},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110648}
}
Kostenlos starten →